about
RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type.The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone.Mutational profile of GNAQQ209 in human tumors.Integrated molecular dissection of the epidermal growth factor receptor (EGFR) [corrected] oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer.Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer.Heat-shock protein 27 (HSP27, HSPB1) is synthetic lethal to cells with oncogenic activation of MET, EGFR and BRAF.Targeted knock-in of the polymorphism rs61764370 does not affect KRAS expression but reduces let-7 levels.Mixed lineage kinase MLK4 is activated in colorectal cancers where it synergistically cooperates with activated RAS signaling in driving tumorigenesis.BCAM and LAMA5 Mediate the Recognition between Tumor Cells and the Endothelium in the Metastatic Spreading of KRAS Mutant Colorectal Cancer.Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.Nucleolin Targeting Impairs the Progression of Pancreatic Cancer and Promotes the Normalization of Tumor Vasculature.Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth.Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer.Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies.Erratum: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patientsHigh-dose vitamin C enhances cancer immunotherapyAdaptive mutability of colorectal cancers in response to targeted therapies
P50
Q27853064-619D9D7F-50DD-4EFE-BD01-4253EC9B7533Q33833156-B3BBB254-2A9F-4353-B5C7-04F24271EFC2Q34061985-D1385AE8-DFE4-4967-B67F-2F78798449B7Q37313504-B5C3AF05-A2D7-4FD1-9607-B85EE2C6C4CAQ37728990-109E7914-0AEF-4CDB-8372-F934DCF0CF8EQ38706872-0356D964-8000-487F-A417-203F243EE374Q38969858-DEB578F9-EDAE-4AA8-B222-48EECAA8E4F7Q39053707-12AAAB40-FE15-4007-9391-7C7E389C9BD4Q39210312-DAF17C25-E55B-4D4E-9852-B24F0CAB003BQ39796525-0E4563FD-64F6-413A-AFC6-D3B06F6D6DFAQ42183079-2C7854C8-4EA3-402E-B71E-A6128A519A09Q48970381-67957A31-0D7D-450B-B2D7-85C6171E621AQ49551908-3305D12A-02D2-4D34-BEE0-3B0B1943F61CQ51752412-1450C4F8-543E-4EC5-9020-2804A405ACDCQ55113736-C0B96A83-3562-40BD-B17E-7875B162AF31Q57280718-1C3406A5-56C8-4DD3-B61F-D41722D51EB7Q89899735-3112C0BA-AA9C-4572-A6D9-2BB37747893EQ91172844-7EAD00C2-B0E3-499C-AACC-4716D396CAE7
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Simona Lamba
@en
Simona Lamba
@nl
type
label
Simona Lamba
@en
Simona Lamba
@nl
prefLabel
Simona Lamba
@en
Simona Lamba
@nl
P31
P496
0000-0003-3207-1594